Keyword: GlaxoSmithKline

The four-year GSK chairman joined the company when the drugmaker was reeling from bribery scandals and poor financial performance.

GlaxoSmithKline has had a Shingrix shortage for months, but now Sen. Schumer said the government shutdown is making the situation worse.

Clovis CEO Patrick Mahaffy is making it clear he’s ready to deal—and doing what he can to make the PARP player a top M&A target.

It wasn't just deals folks were buzzing about in meeting rooms, restaurants and hotel lobbies, as our top FierceBiotech and FiercePharma stories show.

Execs at this year's J.P. Morgan Healthcare Conference agreed the tone was somewhere between gloom and sunshine.

Artificial intelligence is a big buzzword in R&D right now, but at Novartis, it's hard at work in the sales department, too.

CEO Emma Walmsley just put cancer back on the front burner, but with its $5 billion Tesaro buy and in-house candidates, the pipeline is pumping, she says.

What's on Tuesday's talking points memo at JPM? Drug launches, hoped-for FDA nods, deals, rivalries, FDA tea leaves—and one unexpected tax bill.

England's cost watchdog has removed a previous restriction on AZ's Fasenra, allowing it to be funded for an expanded pool of patients.

Turns out, after GlaxoSmithKline walked away from a chance to scoop up Pfizer’s consumer health business in March, it got another opportunity to team up on a deal.